Volume 24, Number 3—March 2018
Research
Characteristics Associated with Negative Interferon-γ Release Assay Results in Culture-Confirmed Tuberculosis Patients, Texas, USA, 2013–2015
Table 3
Variable |
All IGRA results, N = 1,338† | QFT only, n = 875† | T-SPOT.TB only, n = 463† | |||||
---|---|---|---|---|---|---|---|---|
aOR (95% CI) |
p value |
aOR (95% CI) |
p value |
aOR (95% CI) |
p value |
|||
Age in years | 1.02 (1.01–1.03) | <0.001 | 1.02 (1.01–1.04) | <0.001 | 1.02 (1.00–1.03) | 0.01 | ||
Non-Hispanic white race/ethnicity | 2.61 (1.70–4.02) | <0.001 | 2.76 (1.60–4.76) | <0.001 | 2.29 (1.11–4.73) | 0.03 | ||
HIV-positive status | 2.72 (1.56–4.77) | <0.001 | 3.59 (1.86–6.94) | <0.001 | 1.34 (0.44–4.07) | 0.60 | ||
Tested by T-SPOT.TB | 1.58 (1.12–2.24) | 0.01 | – | – | – | – | ||
Time from diagnosis to treatment | 1.00 (1.00–1.01) | 0.046 | 1.00 (1.00–1.01) | 0.22 | 1.01 (1–1.01) | 0.03 |
*aOR, adjusted odds ratio; IGRA, interferon-γ release assay; QFT, QuantiFERON-TB Gold In-Tube; TB, tuberculosis; –, analysis could not be performed.
†Multiple logistic models were run by using data from patients having complete data sets for all the included variables; aORs were from the multiple logistic regression models.
Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.